Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 2/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167345 | 1.00 | PDPK1 (0.35) | PDPK1AAK1ENPP1SSTR4NQO2 | |
| SCHEMBL31728049 | 0.76 | AAK1 (0.33) | PDPK1AAK1MKNK2MTNR1AMTNR1B | |
| SCHEMBL17467122 | 0.73 | BACE1 (0.37) | AAK1SSTR4MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL31728059 | 0.72 | PDPK1 (0.37) | PDPK1SSTR4MKNK2ALDH1A1 | |
| SCHEMBL17981064 | 0.71 | AAK1 (0.34) | PDPK1AAK1SSTR4MKNK2MTNR1A | |
| SCHEMBL20631816 | 0.70 | SSTR4 (0.41) | PDPK1AAK1SSTR4ALDH1A1KMT2A | |
| SCHEMBL13199693 | 0.69 | AAK1 (0.39) | PDPK1AAK1MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL29833741 | 0.69 | AAK1 (0.39) | PDPK1AAK1MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL30204974 | 0.69 | SSTR4 (0.44) | PDPK1AAK1SSTR4MKNK2MTNR1A | |
| SCHEMBL20875099 | 0.69 | PDPK1 (0.36) | PDPK1SSTR4MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4006035-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NEUPHARMA INC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3497087-B1 | PYRROLO[1,2-C]PYRIMIDINE, IMIDAZO[1,5-C]PYRIMIDINE, QUINAZOLINE, PURINE AND IMIDAZO[1,5-A][1,3,5]TRIAZINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NEUPHARMA INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2018-03-15 | — | — | US | disclosed |
| WO-2018035061-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2018-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | PDPK1 102/4885AAK1 604/4885ENPP1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.